Latest News about INCY
Recent news which mentions INCY
Put these 10 stocks on your radar because they may rebound from recent tax-loss selling
November 01, 2021
From MarketWatch
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
October 27, 2021
From Motley Fool
Could This Be the Next Blockbuster Indication for Eli Lilly?
October 21, 2021
From Motley Fool
From Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
From Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
From Benzinga
From Benzinga
More than a quarter of Nasdaq-100 stocks are in bear markets — Wall Street sees a buying opportunity
September 29, 2021
From MarketWatch
Only 47 stocks in the S&P 500 have fallen over the past year — Wall Street predicts they will climb up to 54% in 12 months
September 28, 2021
From MarketWatch
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
From Benzinga
From Benzinga
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
September 23, 2021
Tickers
INCY
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
From Benzinga
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
September 23, 2021
From Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
From Benzinga
10 Biggest Price Target Changes For Thursday
September 23, 2021
From Benzinga
Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD
September 22, 2021
Tickers
INCY
From Benzinga
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
September 22, 2021
From Motley Fool
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
From Benzinga
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
September 22, 2021
Tickers
INCY
From Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
September 21, 2021
From Benzinga
Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada
September 20, 2021
Tickers
INCY
From Benzinga
Is AbbVie a Bad News Buy?
September 19, 2021
From Motley Fool
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.